Jay Bradner is a Physician-Scientist in the Department of Medical Oncology at the Dana-Farber Cancer Institute and an Associate Professor in the Department of Medicine at Harvard Medical School. The research focus of the Bradner laboratory concerns the chemical modulation of chromatin structure and function. The clinical objective of the Bradner group is to deliver novel cancer therapeutics for human clinical investigation.
Dr. Bradner’s awards and honors include the Damon Runyon-Rachleff Innovation Award, the Smith Family Award for Excellence in Biomedical Research, the Dunkin Donuts Rising Star Award and the HMS Distinguished Excellence in Teaching Award. He was elected into the American Society of Clinical Investigation in 2011 and the Alpha Omega Alpha medical society in 2013. His recent research has been published in Nature, Cell, Nature Chemical Biology and the Journal of the American Chemical Society. He has authored more than thirty United States Patent applications and is a scientific founder of Acetylon Pharmaceuticals, SHAPE Pharmaceuticals, Tensha Therapeutics and Syros Pharmaceuticals. Three first-in-class molecules arising from his research are presently studied in open Phase I and Phase II clinical trials. Dr. Bradner also serves on the Board of Directors for the Leukemia & Lymphoma Society and the American Society of Hematology.
Dr. Bradner received his AB from Harvard University, his MD from the University of Chicago, and an MMS from Harvard Medical School. He completed his postgraduate training in Internal Medicine at Brigham & Women's Hospital, followed by fellowships in Medical Oncology and Hematology at Dana-Farber Cancer Institute. Following additional post-doctoral training in Chemistry with Prof. Stuart Schreiber at Harvard University and the Broad Institute, where he now serves as the Associate Director for the Science of Therapeutics. Dr. Bradner joined the research faculty of Dana-Farber in 2008.
« Go Back